Notice of Listing of Members of the National Institutes of Health's Senior Executive Service 2021 Performance Review Board (PRB), 43669-43670 [2021-17039]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices
9. TEKTURNA (aliskiren hemifumarate)
10. VIMOVO (naproxen/esomeprazole
magnesium)
11. VIREAD (tenofovir disoproxil
fumarate)
12. XOFLUZA (baloxavir marboxil)
Center for Devices and Radiological
Health
1. CONTEGRA PULMONARY VALVED
CONDUIT (Humanitarian Device
Exemption (HDE))
2. ELANA SURGICAL KIT (HDE)
3. ENTERRA THERAPY SYSTEM (HDE)
4. LIPOSORBER LA–15 SYSTEM (HDE)
5. MEDTRONIC ACTIVA DYSTONIA
THERAPY (HDE)
6. MINIMALLY INVASIVE DEFORMITY
CORRECTION (MID–C) SYSTEM
7. PLEXIMMUNE IN–VITRO
DIAGNOSTIC TEST (HDE)
8. PULSERIDER ANEURYSM NECK
RECONSTRUCTION DEVICE (HDE)
9. THE TETHER—VERTEBRAL BODY
TETHERING SYSTEM
Dated: August 5, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–17041 Filed 8–9–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jbell on DSKJLSW7X2PROD with NOTICES
Office of the Director, National
Institutes of Health; Notice of Meeting
Notice is hereby given of a meeting of
the HEAL (Helping to End Addiction
Long-Term) Multi-Disciplinary Working
Group.
The meeting will be open to the
public as indicated below via NIH
Videocast. Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The program documents
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the program
documents, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: HEAL MultiDisciplinary Working Group (MDWG)
Meeting.
VerDate Sep<11>2014
17:05 Aug 09, 2021
Jkt 253001
Date: September 1–2, 2021.
Open: September 01, 2021, 10:30 a.m. to
11:30 a.m.
Closed: September 02, 2021, 11:30 a.m. to
4:30 p.m.
Closed: September 02, 2021, 10:30 a.m. to
3:45 p.m.
Agenda: Provide an update on Helping to
End Addiction Long-Term (HEAL) Initiative
projects and obtain expertise from MDWG
relevant to the NIH HEAL Initiative and to
specific HEAL projects.
Videocast: The open portion of the meeting
will be live webcast at: https://
videocast.nih.gov/.
Place: National Institutes of Health,
Building 1, Wilson Hall, 1 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rebecca G Baker, Ph.D.,
Office of the Director, National Institutes of
Health, 1 Center Drive, Room 103A,
Bethesda, MD 20892, (301) 402–1994,
Rebecca.baker@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the Office
of the Director for the NIH HEAL Initiative
website: https://heal.nih.gov/news where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: August 5, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–17012 Filed 8–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Center for Scientific
Review Advisory Council.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
URL for virtual access:—https://
videocast.nih.gov/watch=42556
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Advisory Council.
Date: September 27, 2021.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: Provide advice to the Director,
Center for Scientific Review (CSR), on
matters related to planning, execution,
conduct, support, review, evaluation, and
receipt and referral of grant applications at
CSR.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Bruce Reed, Ph.D., Deputy
Director, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Bethesda, MD 20892, (301) 594–9159,
reedbr@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
public.csr.nih.gov/AboutCSR/Organization/
CSRAdvisoryCouncil, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 5, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–17043 Filed 8–9–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Listing of Members of the
National Institutes of Health’s Senior
Executive Service 2021 Performance
Review Board (PRB)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institutes of
Health (NIH) announces the persons
who will serve on the National
Institutes of Health’s Senior Executive
Service 2021 Performance Review
Board.
FOR FURTHER INFORMATION CONTACT: For
further information about the NIH
Performance Review Board, contact Mr.
Kha Nguyen, Director, Division of
Senior and Scientific Executive
Management, Office of Human
Resources, National Institutes of Health,
Building 31, Room 1C31P, Bethesda,
Maryland 20892, telephone
301.594.3022 (not a toll-free number),
email kha.nguyen@nih.gov.
SUPPLEMENTARY INFORMATION: This
action is being taken in accordance with
SUMMARY:
Center for Scientific Review; Notice of
Meeting
43669
E:\FR\FM\10AUN1.SGM
10AUN1
43670
Federal Register / Vol. 86, No. 151 / Tuesday, August 10, 2021 / Notices
Title 5, U.S.C., section 4314 (c) (4),
which requires that members of
performance review boards be
appointed in a manner to ensure
consistency, stability, and objectivity in
performance appraisals and requires
that notice of the appointment of an
individual to serve as a member be
published in the Federal Register.
The following persons will serve on
the NIH Performance Review Board,
which oversees the evaluation of
performance appraisals of NIH Senior
Executive Service (SES) members:
Alfred Johnson, Chair
Courtney Billet
Michael Gottesman
Darla Hayes
Michael Lauer
Kathleen Stephan
Lawrence Tabak
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Multi-Domain
Amphipathic Helical Peptide for Use as
A Human Therapeutic in Patients With
Atherosclerotic Cardiovascular
Disease, Including Patients
Undergoing Cardiovascular Surgery
Who Are at risk of Acute Kidney Injury
AGENCY:
[FR Doc. 2021–17039 Filed 8–9–21; 8:45 am]
BILLING CODE 4140–01–P
jbell on DSKJLSW7X2PROD with NOTICES
E–114–2004–0–
US–01.
E–114–2004–0–
PCT–02.
E–114–2004–0–
AU–03.
E–114–2004–0–
CA–04.
E–114–2004–0–
EP–05.
E–114–2004–0–
JP–06.
E–114–2004–0–
US–07.
E–114–2004–0–
US–08.
E–114–2004–0–
US–09.
E–114–2004–0–
CH–11.
E–114–2004–0–
DE–12.
E–114–2004–0–
ES–13.
E–114–2004–0–
FR–14.
E–114–2004–0–
GB–15.
E–114–2004–0–
IT–16.
E–114–2004–0–
US–17.
VerDate Sep<11>2014
Patent Application No.
Title
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
Multi-Domain Amphipathic
ods Of Their Use.
All U.S. and foreign patents and
applications claiming priority to any
member of the above.
The patent rights in these inventions
have been assigned or exclusively
17:05 Aug 09, 2021
Jkt 253001
section of
this notice. This is a first notice
intended to apprise the public of a
change in prospective licensee of the
subject intellectual property rights in
the stated field of use.
Only written comments and/or
applications for a license which are
received by the National Heart, Lung,
and Blood Institute on or before August
25, 2021 will be considered.
DATES:
Requests for copies of the
patent application, inquiries, and
ACTION: Notice.
comments relating to the contemplated
an exclusive patent license should be
SUMMARY: The National Heart, Lung, and
directed to: Michael Davis, J.D., Ph.D.,
Blood Institute, an institute of the
Senior Technology Transfer Manager, 31
National Institutes of Health,
Center Drive Room 4A29, MSC2479,
Department of Health and Human
Bethesda, MD 20892–2479, phone
Services, is contemplating the grant of
number 301–451–9032, or
an exclusive patent license to Phyxius
michael.davis4@nih.gov.
Therapeutics, Inc., a start-up company
incorporated as a C corporation under
SUPPLEMENTARY INFORMATION:
the laws of the state of Delaware, to
Intellectual Property
practice the inventions covered by the
HHS.
Dated: August 2, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
NIH REF No.
National Institutes of Health,
patent estate listed in the
SUPPLEMENTARY INFORMATION
ADDRESSES:
Filing Date
Issued Patent
No.
Issue Date
Helical Peptides And Meth-
60/619,392
10/15/04
........................
........................
Helical Peptides And Meth-
PCT/US2005/
10/14/05
........................
........................
Helical Peptides And Meth-
2005295640
10/14/05
2005295640
11/10/11
Helical Peptides And Meth-
2584048
10/14/05
2584048
08/09/16
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
2007–536912
10/14/05
5,091,679
09/21/12
Helical Peptides And Meth-
11/577,259
04/13/07
7,572,771
08/11/09
Helical Peptides And Meth-
12/497,443
07/02/09
8,071,746
12/06/11
Helical Peptides And Meth-
12/766,761
04/23/10
8,148,323
04/03/12
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
05815961.7
10/14/05
1812474
05/26/10
Helical Peptides And Meth-
13/407,132
02/28/12
8,835,378
09/16/14
licensed to the Government of the
United States of America.
The prospective exclusive license
territory may be worldwide and in fields
of use that may be limited to use as a
human therapeutic in patients with
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
atherosclerotic cardiovascular disease
(ASCVD), including patients undergoing
cardiovascular surgery who are at risk of
acute kidney injury.
The patents listed above cover an
invention directed to peptides or
E:\FR\FM\10AUN1.SGM
10AUN1
]]>Agencies
[Federal Register Volume 86, Number 151 (Tuesday, August 10, 2021)]
[Notices]
[Pages 43669-43670]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17039]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Listing of Members of the National Institutes of
Health's Senior Executive Service 2021 Performance Review Board (PRB)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health (NIH) announces the persons
who will serve on the National Institutes of Health's Senior Executive
Service 2021 Performance Review Board.
FOR FURTHER INFORMATION CONTACT: For further information about the NIH
Performance Review Board, contact Mr. Kha Nguyen, Director, Division of
Senior and Scientific Executive Management, Office of Human Resources,
National Institutes of Health, Building 31, Room 1C31P, Bethesda,
Maryland 20892, telephone 301.594.3022 (not a toll-free number), email
[email protected].
SUPPLEMENTARY INFORMATION: This action is being taken in accordance
with
[[Page 43670]]
Title 5, U.S.C., section 4314 (c) (4), which requires that members of
performance review boards be appointed in a manner to ensure
consistency, stability, and objectivity in performance appraisals and
requires that notice of the appointment of an individual to serve as a
member be published in the Federal Register.
The following persons will serve on the NIH Performance Review
Board, which oversees the evaluation of performance appraisals of NIH
Senior Executive Service (SES) members:
Alfred Johnson, Chair
Courtney Billet
Michael Gottesman
Darla Hayes
Michael Lauer
Kathleen Stephan
Lawrence Tabak
Dated: August 2, 2021.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2021-17039 Filed 8-9-21; 8:45 am]
BILLING CODE 4140-01-P
